Journal of Psychoactive Drugs
March 16, 2026
Faith E Lyons, Karilynn M Rockhill, Evelyn J Fox et al.
Expanding regulation and increased use of psychedelic substances requires surveillance of behaviors and health outcomes in the United States. Widely comprehendible terminology is important for surveys. The objective of this study was to determine what psychedelic terminology is preferred among adults who used a psychedelic in the past 12 months. A cross-sectional survey measuring psychedelic...
Australian Journal of Forensic Sciences
March 16, 2026
Kate Brough, Corinna Lange
In April 2024, FSQ Forensic Chemists attended Queensland’s largest mushroom growing operation. Seized items included: 219 50 L plastic tubs of mushrooms in growth medium, bags of dried mushroom material, sterilised grain bags and spores in liquid. In consultation with QPS, six exhibits were selected for illicit drug analysis. Fresh mushrooms were harvested and freeze-dried, and all exhibits...
ACS Pharmacology & Translational Science
March 13, 2026
Bo Jarrett Wood, M Frances Vest, Catharine Carfagno et al.
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for mood and anxiety disorders, the same conditions under which psychedelic-assisted therapies are gaining renewed interest. However, it remains unclear how SSRI treatment may influence sensitivity to psychedelics, particularly through the shared engagement of serotonergic pathways. Here, we used the head-twitch response...
Schizophrenia Research
March 13, 2026
Michel Sabé, Paul Grof, Nathan Sackett et al.
1 citation
Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....
Revista Brasileira Militar de Ciências
March 12, 2026
Tiago de Souza Santos, Joatan Lucas de Sousa Gomes Costa, Carmem Lúcia de Arroxelas Silva
A depressão é um transtorno mental prevalente e incapacitante sendo considerado um problema de saúde pública. É caracterizada por humor deprimido persistente, perda de interesse em atividades diárias, alterações cognitivas e somáticas e, frequentemente, acompanhada por fadiga, alterações no sono ou no apetite. Estima-se que cerca de 20–40% dos pacientes com transtorno depressivo maior não...
BMJ Open
March 12, 2026
Rosalind McAlpine, Magdalena Jaglinska, Krisztina Jedlovszky et al.
Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application. Digital health interventions have the potential to address this limitation by providing structured, accessible and scalable preparation solutions. This randomised controlled feasibility trial aims to evaluate the...
Editora Pasteur eBooks
March 11, 2026
Ana Carolina Baldi Pasqualini, Henrique Wojciechowski Osorio, Veridiana Powarczuk et al.
Introdução: Os transtornos psiquiátricos representam um importante desafio na saúde pública mundial, com impacto significativo na qualidade de vida, funcionalidade e mortalidade dos pacientes. Embora os psicofármacos tradicionais, como antidepressivos, antipsicóticos e estabilizadores de humor sejam amplamente utilizados, muitos indivíduos apresentam resposta insatisfatória, falha terapêutica...
Addiction
March 11, 2026
Christina Mcanulty, Nicolas Garel
Bloy et al. [1] provide an important and methodologically rigorous secondary analysis of the Ketamine for the reduction of Alcoholic Relapse (KARE) trial, examining whether acute psychoactive effects mediate the therapeutic impact of ketamine in alcohol use disorder (AUD). Their finding that dissociative and perceptual effects did not mediate abstinence outcomes is clinically relevant, and...
CNS & Neurological Disorders - Drug Targets
March 11, 2026
Shikha Baghel Chauhan, Naziya Akhtar, Chirag Jain et al.
Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they activate intracellular cascades...
Proceedings of the Royal Society B: Biological Sciences
March 11, 2026
Alexander J. Bradshaw, Cathy Sharp, Breyten Van der Merwe et al.
2 citations
The psychedelic mushroom Psilocybe cubensis is cultivated worldwide for recreational and medicinal use. Described initially from Cuba in 1906, there has been substantial debate about its origin and diversification. The prevailing view is that P. cubensis was inadvertently introduced to the Americas when cattle were introduced to the continent from Africa and Europe (approx. 1500 CE), but that...